

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report: **August 8, 2007**

PHARMATHENE, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware

(State or Other Jurisdiction
of Incorporation)

001-32587

(Commission
File Number)

20-2726770

(IRS Employer
Identification No.)

**One Park Place, Suite 450
Annapolis, Maryland**

(Address of Principal Executive Offices)

21401

(Zip Code)

Registrant's telephone number, including area code:

(410) 269-2600

Healthcare Acquisition Corp.

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01 Other Events.

On August 8, 2007, Healthcare Acquisition Corp. (“HAQ”), now known as PharmAthene, Inc., conducted a conference call with investors concerning the recent merger of its wholly-owned subsidiary, PAI Acquisition Corp., with PharmAthene, Inc., a privately held Delaware corporation, resulting in, among other things, HAQ changing its name to PharmAthene, Inc. and the private company becoming a wholly-owned subsidiary of HAQ under the name PharmAthene US Corporation. A replay of the call will be available until September 8, 2007. In the US (888)203-1112/ International (719) 457-0820, replay passcode: 3318943. A copy of the press release announcing the call is attached to this Report as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d)

<u>Name</u>	<u>Description</u>
Exhibit 99.1	Press Release dated August 7, 2007

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 8, 2007

PHARMATHENE, INC.

By: /s/ David P. Wright

David P. Wright
President

FOR IMMEDIATE RELEASE

**PHARMATHENE TO HOLD INVESTOR CALL REGARDING MERGER WITH HAQ
New Common Stock Symbol is 'PIP'**

ANNAPOLIS, MD — August 7, 2007 —

What: PharmAthene, Inc. (AMEX:PIP) to host a conference call to discuss merger with HAQ.

When: Wednesday, August 8, 2007 1:00 PM EST.

How: In the US (877) 879-6203/International (719) 325-4760
Please refer to the Confirmation Code: 3318943

A playback of the call will be available until September 8, 2007
In the US (888)203-1112/ International (719) 457-0820
Replay Passcode: 3318943

Contact: Erica Greenman
Hullin Metz & Co.
Office: (212) 752-1044/ Mobile (917) 822-7702
Erica@hmccllc.com

Additional Information

PHARMATHENE CLAIMS THE PROTECTION OF THE SAFE HARBOR FOR "FORWARD-LOOKING STATEMENTS" WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. FORWARD-LOOKING STATEMENTS ARE STATEMENTS THAT ARE NOT HISTORICAL FACTS. SUCH FORWARD-LOOKING STATEMENTS, BASED UPON THE CURRENT BELIEFS AND EXPECTATIONS OF MANAGEMENT OF PHARMATHENE REGARDING, AMONG OTHER THINGS, THE POTENTIAL DETERMINATIONS BY A COURT OF CHANCERY IN DELAWARE AS TO THE VALIDITY OF THE APPROVAL OF THE MERGER, WHICH CANNOT BE PREDICTED WITH CERTAINTY. NO ASSURANCES CAN BE GIVEN THAT OTHER PARTIES WILL NOT OPPOSE CONFIRMATION OF SUCH VALIDITY.

About PharmAthene, Inc.

PharmAthene was a privately-held biodefense company, was formed in 2001 to meet the critical needs of the United States by developing biodefense products. PharmAthene is dedicated to the rapid development of important and novel biotherapeutics to address biological pathogens and chemicals that may be used as weapons of bioterror. PharmAthene's lead programs include Valortim™ and Protexia®. For more information on PharmAthene, please visit its website at www.PharmAthene.com. Following approval of the merger at HAQ's Special Meeting of Stockholders held on Friday, August 3, 2007, the name of PharmAthene was changed to "PharmAthene US Corporation."
